News Feature | Published:

After Theranos

Nature Biotechnology volume 35, pages 1115 (2017) | Download Citation

The implosion of blood diagnostics developer Theranos has raised the question: What is feasibly detectible in a drop of blood? Emily Waltz reports.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Procedia Eng. 25, 63–66 (2011).

  2. 2.

    et al. Clin. Chim. Acta 411, 868–873 (2010).

  3. 3.

    et al. Biosens. Bioelectron. 85, 1–7 (2016).

  4. 4.

    et al. Biosens. Bioelectron. 70, 61–68 (2015).

  5. 5.

    et al. J. Vis. Exp. 93, e51743 (2014).

  6. 6.

    et al. J. Clin. Microbiol. 53, 3458–3465 (2015).

Download references

Author information

Affiliations

  1. Nashville, Tennessee

    • Emily Waltz

Authors

  1. Search for Emily Waltz in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.3761

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing